-

Phoenix and Raven Become First Canadian Telehealth Platforms to Offer Generic Semaglutide Direct to Patients

Eligible Canadians can now access Health Canada–approved generic semaglutide directly, by prescription, starting at $124.99

TORONTO--(BUSINESS WIRE)--Today, Phoenix and Raven, leading Canadian digital health providers, announced the launch of generic semaglutide for direct-to-patient access in Canada, making them the first telehealth platform in the country to bring this medication to customers. Phoenix and Raven are looking to set the new pricing for optimal access with orders starting at $124.99, delivered by prescription across Canada.

For a long time, the conversation around semaglutide in Canada was simple: most people couldn't get it, and those who could, often couldn't afford it. That changes today.

Share

The launch follows Health Canada's recent approval on April 28, 2026, making Canada the first G7 country to offer a generic semaglutide. With multiple generic manufacturers now authorized to supply the Canadian market, today's launch signals the beginning of a new era of accessibility for a medication that has fundamentally reshaped conversations about chronic disease, weight, and preventive health.

Demand ahead of launch has been significant, with thousands of Canadians having registered interest through the platform's waitlist. The generic semaglutide offered by Phoenix and Raven is supplied and distributed domestically.

"For a long time, the conversation around semaglutide in Canada was simple: most people couldn't get it, and those who could, often couldn't afford it. That changes today,” says Dr. Mark Broussenko, Medical Director at Phoenix and Raven.

“Generic approval is a turning point, not just for this medication, but for how Canadians think about access to care. When effective, evidence-based treatment becomes accessible and affordable, that's not just good for individual patients, it has the potential to meaningfully shift outcomes on a national level. This is what progress in Canadian healthcare looks like, and we are proud that Phoenix and Raven are the first digital telehealth providers to offer generic semaglutide to patients."

Phoenix and Raven are Canada’s leading telehealth platforms providing trusted online medical care designed for both men and women’s needs and lifestyle. Both platforms facilitate access to licensed Canadian physicians, treatment options, and free, discreet shipping of prescription medication from coast to coast. Semaglutide is available by prescription only, with eligibility determined by a licensed Canadian prescriber. Patients are encouraged to speak with their provider to find out if it’s right for them. Visit phoenix.ca and getraven.com to learn more.

ABOUT PHOENIX & RAVEN

Phoenix is Canada’s leading digital health clinic for men, specializing in three areas of treatment – erectile dysfunction, weight loss, and hair loss. Phoenix also launched Raven, a telehealth platform built to support women through every stage of their health journey, tailored to their needs, including treatments for weight loss, and hair loss. Both platforms facilitate access to licensed Canadian prescribers, treatment options, and free, discreet shipping of prescription medication from coast to coast. Visit phoenix.ca and getraven.com to learn more.

Contacts

MEDIA CONTACT

Kayla Moyes
Director of Corporate Communications, Talk Shop Media
kayla.moyes@talkshopmedia.com
250-218-9276

Phoenix LogoPhoenix Logo

Phoenix


Release Summary
On May 20, Phoenix and Raven become first Canadian telehealth platforms to offer generic semaglutide direct to patients, starting at $124.99.
Release Versions

Contacts

MEDIA CONTACT

Kayla Moyes
Director of Corporate Communications, Talk Shop Media
kayla.moyes@talkshopmedia.com
250-218-9276

More News From Phoenix

New Data from Phoenix Reveals Canadians Turning to Dr. Google for Personal Care Goals in 2026, AI for Recommended Treatments

TORONTO--(BUSINESS WIRE)--New data from Phoenix found 38% of Canadians don’t consider their health and wellness goals to be enough of a reason to book a doctor’s appointment....

New Poll Reveals Canadians Lack Understanding of Obesity as a Chronic Disease, Stigma Likely Bleeds Into Treatment

TORONTO--(BUSINESS WIRE)--Phoenix released new poll data with insights from over 1,500 Canadians on sentiments around weight loss and the use of GLP-1s...

We Need to Talk About Erectile Dysfunction: 38% of Canadian Men Don’t Know You Need a Prescription for ED Medication

TORONTO--(BUSINESS WIRE)--Phoenix’s survey of more than 1,500 Canadians found that there is a significant lack of awareness around erectile dysfunction and its treatment....
Back to Newsroom